Literature DB >> 17991353

Pediatric non-Hodgkin's lymphoma.

Thomas G Gross1, Amanda M Termuhlen.   

Abstract

Non-Hodgkin's lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

Entities:  

Mesh：

Year:  2007        PMID： 17991353     DOI： 10.1007/s11912-007-0064-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  43 in total

1.  Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Authors:  A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature.

Authors:  Shimareet Kumar; Stefania Pittaluga; Mark Raffeld; Michael Guerrera; Nita L Seibel; Elaine S Jaffe
Journal:  Pediatr Dev Pathol       Date:  2005-02-23

3.  Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution.

Authors:  S B Murphy; D L Fairclough; R E Hutchison; C W Berard
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

4.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

Authors:  Ilske Oschlies; Wolfram Klapper; Martin Zimmermann; Matthias Krams; Hans-Heinrich Wacker; Birgit Burkhardt; Lana Harder; Reiner Siebert; Alfred Reiter; Reza Parwaresch
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

5.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  MALT lymphoma in children: a report from the NHL-BFM Study Group.

Authors:  Alexander Claviez; Ulrike Meyer; Christoph Dominick; James F Beck; Manfred Rister; Markus Tiemann
Journal:  Pediatr Blood Cancer       Date:  2006-08       Impact factor: 3.167

7.  Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.

Authors:  L Brugières; P Quartier; M C Le Deley; H Pacquement; Y Perel; C Bergeron; C Schmitt; J Landmann; C Patte; M J Terrier-Lacombe; G Delsol; O Hartmann
Journal:  Ann Oncol       Date:  2000-01       Impact factor: 32.976

8.  Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers.

Authors:  Vani Sabesan; Mitchell S Cairo; Mark A Lones; Sherrie L Perkins; Erin Morris; Richard Sposto; Carmella Van De Ven; Bruce Shiramizu
Journal:  J Pediatr Hematol Oncol       Date:  2003-02       Impact factor: 1.289

9.  Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.

Authors:  Andishe Attarbaschi; Michael Dworzak; Manuel Steiner; Christian Urban; Franz-Martin Fink; Alfred Reiter; Helmut Gadner; Georg Mann
Journal:  Pediatr Blood Cancer       Date:  2005-01       Impact factor: 3.167

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307
View more
  11 in total

1.  Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India.

Authors:  Marie Therese Manipadam; Sheila Nair; Auro Viswabandya; Leni Mathew; Alok Srivastava; Mammen Chandy
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling.

Authors:  Karen E Deffenbacher; Javeed Iqbal; Warren Sanger; Yulei Shen; Cynthia Lachel; Zhongfeng Liu; Yanyan Liu; Megan S Lim; Sherrie L Perkins; Kai Fu; Lynette Smith; James Lynch; Louis M Staudt; Lisa M Rimsza; Elaine Jaffe; Andreas Rosenwald; German K Ott; Jan Delabie; Elias Campo; Randy D Gascoyne; Mitchell S Cairo; Dennis D Weisenburger; Timothy C Greiner; Thomas G Gross; Wing C Chan
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

3.  Disease patterns of pediatric non-Hodgkin lymphoma: A study from a developing area in Egypt.

Authors:  Laila M Sherief; Usama R Elsafy; Elhamy R Abdelkhalek; Naglaa M Kamal; Doaa M Youssef; Rabab Elbehedy
Journal:  Mol Clin Oncol       Date:  2014-09-24

Review 4.  Whole-body diffusion-weighted imaging for staging malignant lymphoma in children.

Authors:  Thomas C Kwee; Taro Takahara; Malou A Vermoolen; Marc B Bierings; Willem P Mali; Rutger A J Nievelstein
Journal:  Pediatr Radiol       Date:  2010-07-30

5.  Effects of chemotherapy on the brain in childhood: diffusion tensor imaging of subtle white matter damage.

Authors:  Shigemi Morioka; Masafumi Morimoto; Kei Yamada; Tatsuji Hasegawa; Takashi Morita; Masaharu Moroto; Kenichi Isoda; Tomohiro Chiyonobu; Toshihiko Imamura; Akira Nishimura; Akira Morimoto; Hajime Hosoi
Journal:  Neuroradiology       Date:  2013-07-27       Impact factor: 2.804

6.  Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Elizabeth C Bluhm; Cécile Ronckers; Robert J Hayashi; Joseph P Neglia; Ann C Mertens; Marilyn Stovall; Anna T Meadows; Pauline A Mitby; John A Whitton; Sue Hammond; Joseph D Barker; Sarah S Donaldson; Leslie L Robison; Peter D Inskip
Journal:  Blood       Date:  2008-02-07       Impact factor: 22.113

Review 7.  Antibody therapies for lymphoma in children.

Authors:  Verena de Zwart; Samantha C Gouw; Friederike A G Meyer-Wentrup
Journal:  Cochrane Database Syst Rev       Date:  2016-01-19

8.  Pediatric lymphomas in Brazil.

Authors:  Gabriela Gualco; Claudete E Klumb; Glen N Barber; Lawrence M Weiss; Carlos E Bacchi
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients.

Authors:  Suying Lu; Xiaoqin Zhu; Wei Li; Huimou Chen; Dalei Zhou; Zijun Zhen; Feifei Sun; Junting Huang; Jia Zhu; Juan Wang; Yizhuo Zhang; Xiaofei Sun
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

10.  Novel Bruton's tyrosine kinase inhibitors currently in development.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Onco Targets Ther       Date:  2013-03-06       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.